EA201990949A1 - Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине - Google Patents
Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицинеInfo
- Publication number
- EA201990949A1 EA201990949A1 EA201990949A EA201990949A EA201990949A1 EA 201990949 A1 EA201990949 A1 EA 201990949A1 EA 201990949 A EA201990949 A EA 201990949A EA 201990949 A EA201990949 A EA 201990949A EA 201990949 A1 EA201990949 A1 EA 201990949A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- organic nitro
- sulphoxialkyl
- medicine
- pharmaceutical compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 150000002828 nitro derivatives Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- -1 (2- (3,3-dinitroazetidin-1-yl) -2-oxoethyl) sulfinyl Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408182P | 2016-10-14 | 2016-10-14 | |
| PCT/US2017/056454 WO2018071741A1 (en) | 2016-10-14 | 2017-10-13 | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201990949A1 true EA201990949A1 (ru) | 2019-10-31 |
Family
ID=61906413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990949A EA201990949A1 (ru) | 2016-10-14 | 2017-10-13 | Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11008287B2 (OSRAM) |
| EP (1) | EP3526195A4 (OSRAM) |
| JP (1) | JP7332469B2 (OSRAM) |
| KR (1) | KR20190128619A (OSRAM) |
| CN (1) | CN110352190A (OSRAM) |
| AU (2) | AU2017342436C1 (OSRAM) |
| BR (1) | BR112019007453A2 (OSRAM) |
| CA (1) | CA3040479A1 (OSRAM) |
| EA (1) | EA201990949A1 (OSRAM) |
| IL (1) | IL265970B (OSRAM) |
| MX (1) | MX2019004280A (OSRAM) |
| SG (1) | SG11201903312VA (OSRAM) |
| WO (1) | WO2018071741A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| WO2013052803A2 (en) | 2011-10-07 | 2013-04-11 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
| US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
| AU2017207304B2 (en) | 2016-01-11 | 2022-05-26 | Epicentrx, Inc. | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone |
| CA3040479A1 (en) | 2016-10-14 | 2018-04-19 | Epicentrx, Inc. | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine |
| IL311727A (en) | 2017-07-07 | 2024-05-01 | Epicentrx Inc | Preparations for intravenous administration of medical substances |
| WO2019164593A2 (en) | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
| AU2022294071A1 (en) * | 2021-06-16 | 2024-01-04 | Epicentrx, Inc. | Organonitro and sulfoxyalkyl organonitro compounds for use in treating medical disorders |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2978453A (en) | 1956-12-12 | 1961-04-04 | Aerojet General Co | 3, 3, 5, 5-tetranitropiperidine |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS5511509A (en) | 1978-07-07 | 1980-01-26 | Toomasu Gorudon Robaato | Cancer therapy |
| US4935450A (en) | 1982-09-17 | 1990-06-19 | Therapeutical Systems Corporation | Cancer therapy system for effecting oncolysis of malignant neoplasms |
| GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| US4584130A (en) | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
| GB8728418D0 (en) | 1987-12-04 | 1988-01-13 | Jenkins T C | Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5693794A (en) | 1988-09-30 | 1997-12-02 | The United States Of America As Represented By The Secretary Of The Navy | Caged polynitramine compound |
| JP2659614B2 (ja) | 1990-11-13 | 1997-09-30 | 株式会社日立製作所 | 表示制御装置 |
| TW198712B (OSRAM) * | 1991-04-17 | 1993-01-21 | Hoffmann La Roche | |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| WO1993008842A1 (en) | 1991-11-08 | 1993-05-13 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
| US5336784A (en) | 1993-06-07 | 1994-08-09 | The Regents Of The University Of California | Synthesis of 1,3,3-trinitroazetidine |
| JP3211892B2 (ja) | 1994-05-27 | 2001-09-25 | セイジィ ファーマスーティカルス インコーポレーテッド | 肛門疾患を治療する窒素酸化物供与体及び方法 |
| ATE186222T1 (de) | 1995-03-14 | 1999-11-15 | Siemens Ag | Ultraschallzerstäuber mit abnehmbarer präzisionsdosiereinheit |
| ES2177771T3 (es) | 1995-03-14 | 2002-12-16 | Siemens Ag | Dispositivo atomizador ultrasonico con unidad desmontable de dosificacion de precision. |
| AU5798996A (en) | 1995-05-15 | 1996-11-29 | Sachs, Michael C. | Adnaz, compositions and processes |
| US5580988A (en) | 1995-05-15 | 1996-12-03 | The United States Of America As Represented By The Secretary Of The Army | Substituted azetidines and processes of using them |
| US5898038A (en) | 1996-03-19 | 1999-04-27 | Board Of Regents, The University Of Texas System | Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors |
| AU738341B2 (en) * | 1996-10-11 | 2001-09-13 | Abbott Gmbh & Co. Kg | Asparate ester inhibitors of interleukin-1beta converting enzyme |
| JP2001501159A (ja) | 1996-10-15 | 2001-01-30 | イーストマン ケミカル カンパニー | 爆薬配合物 |
| GB9720797D0 (en) | 1997-09-30 | 1997-12-03 | Rhodes John | Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome |
| US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
| US6056966A (en) | 1998-05-18 | 2000-05-02 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for treating impotence |
| US7635722B1 (en) | 1998-07-27 | 2009-12-22 | Saint Jude Pharmaceuticals, Inc. | Chemical induced intracellular hyperthermia |
| US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| US6391911B1 (en) | 1999-02-26 | 2002-05-21 | Robert E. Bases | Coadministration of lucanthone and radiation for treatment of cancer |
| US20020077276A1 (en) | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
| US6245799B1 (en) | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| ES2244599T3 (es) | 2000-04-10 | 2005-12-16 | Pfizer Products Inc. | Compuestos de benzamido-piperidina como antagonistas de la sustancia p. |
| JP2002069057A (ja) | 2000-07-07 | 2002-03-08 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| DE10111049A1 (de) | 2001-03-06 | 2002-09-12 | Beiersdorf Ag | Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2491127A1 (en) | 2002-07-03 | 2004-01-15 | Nitromed, Inc. | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| AU2003282534A1 (en) | 2002-10-07 | 2004-05-04 | Radiorx, Inc. | X-nitro compounds, pharmaceutical compositions thereof and uses therof |
| EP1603933A2 (en) | 2003-03-13 | 2005-12-14 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods of use |
| WO2004113281A1 (en) | 2003-06-25 | 2004-12-29 | Je Il Pharmaceutical Co., Ltd. | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them |
| AU2004257693B8 (en) | 2003-07-09 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
| GB0326047D0 (en) | 2003-11-07 | 2003-12-10 | Univ Sheffield | Substance |
| US7829708B2 (en) | 2004-09-08 | 2010-11-09 | Chelsea Therapeutics, Inc. | Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation |
| US20060264415A1 (en) * | 2005-04-01 | 2006-11-23 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US20070135380A1 (en) | 2005-08-12 | 2007-06-14 | Radiorx, Inc. | O-nitro compounds, pharmaceutical compositions thereof and uses thereof |
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
| GB0611405D0 (en) | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
| US8122281B2 (en) | 2007-04-13 | 2012-02-21 | International Business Machines Corporation | System and method for dependent failure-aware allocation of distributed data-processing systems |
| US8471041B2 (en) | 2010-02-09 | 2013-06-25 | Alliant Techsystems Inc. | Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same |
| US20120149678A1 (en) | 2010-12-09 | 2012-06-14 | Oronsky Bryan T | Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto |
| US8664247B2 (en) * | 2011-08-26 | 2014-03-04 | Radiorx, Inc. | Acyclic organonitro compounds for use in treating cancer |
| WO2013052803A2 (en) | 2011-10-07 | 2013-04-11 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| EP2763667B1 (en) * | 2011-10-07 | 2022-10-26 | EpicentRx, Inc. | Organonitro thioether compounds and medical uses thereof |
| US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
| US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
| AU2017207304B2 (en) | 2016-01-11 | 2022-05-26 | Epicentrx, Inc. | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone |
| CA3040479A1 (en) | 2016-10-14 | 2018-04-19 | Epicentrx, Inc. | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine |
| IL311727A (en) | 2017-07-07 | 2024-05-01 | Epicentrx Inc | Preparations for intravenous administration of medical substances |
-
2017
- 2017-10-13 CA CA3040479A patent/CA3040479A1/en active Pending
- 2017-10-13 JP JP2019519978A patent/JP7332469B2/ja active Active
- 2017-10-13 MX MX2019004280A patent/MX2019004280A/es unknown
- 2017-10-13 KR KR1020197013789A patent/KR20190128619A/ko not_active Withdrawn
- 2017-10-13 US US16/341,538 patent/US11008287B2/en active Active
- 2017-10-13 BR BR112019007453A patent/BR112019007453A2/pt not_active Application Discontinuation
- 2017-10-13 EP EP17859688.8A patent/EP3526195A4/en not_active Withdrawn
- 2017-10-13 WO PCT/US2017/056454 patent/WO2018071741A1/en not_active Ceased
- 2017-10-13 EA EA201990949A patent/EA201990949A1/ru unknown
- 2017-10-13 SG SG11201903312VA patent/SG11201903312VA/en unknown
- 2017-10-13 CN CN201780077202.8A patent/CN110352190A/zh active Pending
- 2017-10-13 AU AU2017342436A patent/AU2017342436C1/en active Active
-
2019
- 2019-04-11 IL IL265970A patent/IL265970B/en unknown
-
2022
- 2022-05-12 AU AU2022203169A patent/AU2022203169B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201903312VA (en) | 2019-05-30 |
| CN110352190A (zh) | 2019-10-18 |
| BR112019007453A2 (pt) | 2019-07-16 |
| EP3526195A4 (en) | 2020-05-20 |
| JP2019532067A (ja) | 2019-11-07 |
| AU2022203169A1 (en) | 2022-06-02 |
| KR20190128619A (ko) | 2019-11-18 |
| JP7332469B2 (ja) | 2023-08-23 |
| MX2019004280A (es) | 2019-09-18 |
| WO2018071741A8 (en) | 2019-05-31 |
| WO2018071741A1 (en) | 2018-04-19 |
| EP3526195A1 (en) | 2019-08-21 |
| AU2017342436B2 (en) | 2022-05-19 |
| IL265970A (en) | 2019-06-30 |
| US11008287B2 (en) | 2021-05-18 |
| AU2017342436A1 (en) | 2019-05-02 |
| AU2017342436C1 (en) | 2022-11-03 |
| CA3040479A1 (en) | 2018-04-19 |
| AU2022203169B2 (en) | 2024-04-18 |
| IL265970B (en) | 2022-03-01 |
| US20200157047A1 (en) | 2020-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201990949A1 (ru) | Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине | |
| CY1124257T1 (el) | N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA | |
| CY1124084T1 (el) | Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων | |
| EP3895717C0 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLORECTAL CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE | |
| EA201790174A1 (ru) | Антипролиферативные соединения и способы их применения | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| MX2023002507A (es) | Inhibidores de cd73. | |
| MX2022005256A (es) | Inhibidores de cd73. | |
| EA202190681A1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов | |
| EA202191476A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF OPHTHALMIC DISORDERS | |
| EA202090414A1 (ru) | Соединения и их применение | |
| EA201991374A1 (ru) | Водорастворимое производное эпиаллопрегнанолона и его применение | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
| WO2017117070A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| EP3846803A4 (en) | Macrocyclic compounds for the treatment of medical disorders | |
| MX386761B (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo. | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| EP3620457A4 (en) | COMPOUND DERIVED FROM PYRIMIDINE, OPTICAL ISOMER, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING A TYRO 3-RELATED DISEASE, CONSIDERING IT AS AN ACTIVE INGREDIENT | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения |